Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia Administered to Patients With High-Risk Sarcoma Receiving Intensive Chemotherapy (Adriamycin and Ifosfamide (AI))

NCT00038311 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00038311
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00038311 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia Administered to Patients With High-Risk Sarcoma Receiving Intensive Chemotherapy (Adriamycin and Ifosfamide (AI))
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2000
Completion date
March 31, 2003
Enrollment
120
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

sarcoma